Gastrointestinal symptoms (nausea, diarrhea, constipation, abdominal pain) are most common, typically occurring during dose escalation and often improving with continued use
Learn more: Cell by Cell Press Cell Press #neuroscience #neurology #durgdevelopment #clinicaltrials #diseasemodifyingtherapy #Alzheimer #Alzheimersdisease #dementia #cognitivedecline #tau #tauprotein #tauopathy #pathophysiology #neurodegeneration #neurodegenerativediseases #PET #PETimaging #neuroradiology #brainimaging #biomarkers #molecularimaging #tautherapy #ASO #anstisenseoligonucelotides #amyloid #immunization #ATN #immunotherapies #drugdiscovery #precisionmedicine #outcomes #outcomeresearch #trialdesign #adaptivedesign Figure: Lessons from anti-tau immunotherapies: Optimization of tau targeting and clinical trial design
Nevertheless, fundamental pharmacokinetic constraints related to half-life and accumulation will continue to govern which molecules can benefit from improved formulation, and the negative-selection framework remains applicable across delivery technologies
Written by Benton Lowey-Ball, BS Behavioral Neuroscience Sources: Bustamante, J., Rimola, A., Ventura, P
